Business
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting
Company to showcase pipeline developments across lead programs in recurrent glioblastoma and leptomeningeal metastases in two poster presentations at SNMMI
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"Company to showcase pipeline developments across lead programs in recurrent glioblastoma and leptomeningeal metastases in two poster presentations at SNMMI Annual Meeting\nAUSTIN, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois. In addition, at the SNMMI Annual Meeting, Norman LaFrance, M.D., Chief Medical Officer, will present data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM) and leptomeningeal metastases (LM), respectively. Details of SNMMI poster presentations: TitleSafety and Feasibility Results from a Phase 1/2 Clinical Trial of 186RNL (Rhenium-186Nanoliposome) (186Re) Obisbemeda in Recurrent Glioma: The ReSPECT-GBM Trial [P988] DateJune 26, 2023, 10:05-10:15 a.m. CT / 11:05 a.m. ET SessionSS25 Head/Neck and Melanoma TitlePreliminary Clinical Data in The Phase 1/2a Dose Escalation Trial of 186RNL (Rhenium-186Nanoliposome) (186Re) Obisbemeda in Leptomeningeal Metastases (LM): The ReSPECT-LM Trial [P978] DateJune 27, 2023, 1:00-1:30 p.m. CT / 2:00-2:30 p.m. ET SessionMTA06-B13 Meet the Author: Neurosciences/Oncology, Basic & Translational - Group B A copy of the presentations will be made available under the Presentations tab of the Investors section of the Company’s website following the meeting at https://ir.plustherapeutics.com. About Plus TherapeuticsPlus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has bu...